All Cause Mortality
All-cause mortality was higher in patients treated with tigecycline than comparators in a meta-analysis of clinical trials. The cause of this mortality risk difference of 0.6% (95% CI 0.1, 1.2) has not been established. Tigecycline for injection should be reserved for use in situations when alternative treatments are not suitable.
FDA and Industry Communications
Patient Counseling Information